News Sentiment

ORGO sentiment intelligence

Organogenesis Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 2.40 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+1.7% over one week, +2.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 1.7% Price digesting
Trend fit Trend inactive 2.6% over four weeks
Fair value -30.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 32
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
GlobeNewswire 4
TradingView 4
Seeking Alpha 4
Investing.com 3
Market source 2
simplywall.st 2
Ad-hoc-news.de 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 14
Deals and strategy 2
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
TradingView Direct company coverage

Price to earnings forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31

This article provides the "Price to earnings forward" value for Organogenesis Holdings, Inc. Class A (LSX:A2PA31). It indicates the period, value, and change percentage, noting that the data was made by humans. The article is a financial data point from TradingView.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 19:39
Source
TradingView
Stock Titan Direct company coverage

ORGO SEC Filings - Organogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Organogenesis Holdings Inc. (ORGO) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. Recent filings highlight a significant downturn in Q1 2026 financial performance, with an 58%

Tone
Negative 20/100
Event
Earnings
Published
29 Jun 2026 18:39
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31

This article provides the enterprise value to EBIT forward for Organogenesis Holdings, Inc. Class A, traded on the Lang & Schwarz Exchange under the symbol A2PA31. It appears to be a financial data point from a trading platform without additional commentary or analysis.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:13
Source
TradingView
TradingView Direct company coverage

Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO)

The article provides actuals and estimates for Organogenesis Holdings Inc. (ORGO) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers earnings, revenue, EBITDA, and employee count, alongside answers to frequently asked ques

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:40
Source
TradingView
Stock Titan Direct company coverage

Organogenesis (NASDAQ: ORGO) investors reelect full board and approve pay

Organogenesis Holdings Inc. (NASDAQ: ORGO) shareholders reelected the entire board of directors, approved executive compensation on an advisory basis, and ratified RSM US LLP as their independent registered public accounting firm at their 2026 Annual Meeting. All nine director no

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:41
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of Organogenesis Holdings, Inc. Class A – DUS:2PQ

This article provides general information about Organogenesis Holdings, Inc. Class A (DUS:2PQ) on the Dusseldorf Stock Exchange. It notes that the market is currently closed and briefly touches on data sources and copyright information related to the financial data presented. The

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 23:10
Source
TradingView
Stock Titan Direct company coverage

Organogenesis (NASDAQ: ORGO) posts 58% Q1 revenue drop and deeper loss

Organogenesis Holdings Inc. reported a significant downturn for Q1 2026, with net product revenue plunging 58% to $36.3 million, primarily due to a 63% drop in Advanced Wound Care revenue. The company's net loss widened to $53.2 million, or $(0.44) per share, compared to a $18.8

Tone
Negative 29/100
Event
Earnings
Published
18 May 2026 22:10
Source
Stock Titan
FinancialContent Direct company coverage

Organogenesis Holdings Inc. - Class A (NQ: ORGO)

This article provides recent news headlines related to Organogenesis Holdings Inc. - Class A (ORGO), though most of the listed articles are from April 2021 and discuss other companies like Repligen, Quanterix, Reviva Pharmaceuticals, Align Technology, Novocure, and various biotec

Tone
Negative 32/100
Event
Market update
Published
15 May 2026 08:39
Source
FinancialContent
Stock Titan Direct company coverage

Organogenesis (ORGO) CCO exercises option, now holds 900,682 shares

Organogenesis Holdings Inc.'s Chief Commercial Officer, Brian Grow, exercised stock options to acquire 958 shares of Class A Common Stock at $1.24 per share on January 10, 2025. This transaction increased his direct holdings to 900,682 shares. The Form 4 filing indicates a neutra

Tone
Neutral 50/100
Event
Market update
Published
25 Apr 2026 01:38
Source
Stock Titan
GlobeNewswire Direct company coverage

Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm

The Portnoy Law Firm has announced an investigation into Organogenesis Holdings, Inc. for potential securities fraud, encouraging investors to contact them to discuss legal rights and options for recovery. This follows a significant 10.14% stock price drop on December 30, 2025, a

Tone
Negative 27/100
Event
Regulatory and legal
Published
16 Apr 2026 08:39
Source
GlobeNewswire
Sahm Direct company coverage

What's Going On With Organogenesis Stock On Wednesday?

Organogenesis Holdings Inc. (NASDAQ: ORGO) shares are up in premarket trading on Wednesday due to positive clinical trial results for its PuraPly AM product, which showed statistically significant wound closure for diabetic foot ulcers. The company also confirmed plans to submit

Tone
Positive 63/100
Event
Earnings
Published
09 Apr 2026 07:09
Source
Sahm
NEREJ Direct company coverage

Newmark brokers Lightstone’s $68 million acquisition of 122,507 s/f 100 Technology Way

Lightstone, a leading real estate company, has acquired 100 Technology Way in Smithfield, RI, for $68 million, expanding its life science portfolio. The 122,507 s/f Class A cGMP biomanufacturing facility is fully leased to Organogenesis, who is investing $100 million in renovatio

Tone
Positive 72/100
Event
Deals and strategy
Published
08 Apr 2026 16:40
Source
NEREJ